BioTuesdays

Tag - oral insulin

Feature

Oramed sees value creating events through 2016

By Len Zehr Oramed Pharmaceuticals’ (NASDAQ:ORMP) oral insulin development program has multiple value-creating events in the works through 2016. They include completion of an ongoing Phase 2b FDA multi-site study for...

December 1, 2015
Feature

Oramed readies oral insulin study in U.S.

By Len Zehr Oramed Pharmaceuticals (NASDAQ:ORMP) is awaiting a decision from the FDA, possibly later this week, to conduct a sub-study of the safety of its oral insulin candidate, ORMD-0801, before proceeding to a...

May 7, 2013